Strengthening the production base through production equipment upgrades
First written in FY2017-Q1. 14 of 30 entries say "Advanced", first in FY2017-Q2. Latest entry: FY2026.
126 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「Capital expenditures for the fiscal year focused primarily on the construction and expansion of production facilities, totaling ¥80,809 million.」
Capital expenditures totaled ¥80,809 million, with construction progressing on the new Chiba Yakult Plant and Yakult U.S.A. Plant No. 2. The planned investment for the U.S. plant is ¥72.16 billion, with completion scheduled for March 2027 and daily production capacity of 1.79 million bottles. - 2026-05-12AdvancedFinancial results presentation materials
「Capital expenditures 49,603 88.2 80,809 162.9 85,000 105.2」
Capital expenditures totaled ¥80,809 million, with ¥85,000 million forecast for the fiscal year ending March 2027. Actual and planned capital expenditures are higher than the previous fiscal year’s ¥49,603 million. - FY2025AdvancedAnnual report
「Capital expenditures for the fiscal year focused primarily on the construction and upgrading of production facilities, totaling ¥49,603 million.」
Capital expenditures totaled ¥49,603 million, with construction progressing on the new Chiba Yakult Plant and Plant No. 2 in the United States. The U.S. plant is planned with investment of ¥59.363 billion, scheduled completion in September 2026 and daily production capacity of 1.79 million bottles. - FY2025-H1AdvancedAnnual report
「Yakult U.S.A. Inc. (California, U.S.) Beverage and food manufacturing and sales business (Americas) Construction of Plant No. 2 56,700 1,471 Internal funds Borrowings October 2024 March 2026 Daily production capacity of 1.79 million bottles」
The equipment plan for Plant No. 2 in the United States was finalized, with planned investment of ¥56.7 billion, payments made to date of ¥1.471 billion, work commencing in October 2024, scheduled completion in March 2026 and daily production capacity of 1.79 million bottles. - FY2024RaisedAnnual report
「Chiba Yakult Plant Co., Ltd. (Chiba and Sakura, Chiba Prefecture) Construction of new plant 51,835 — Internal funds Borrowings Leases 2024 2027 Daily production capacity of 2.6 million bottles」
For the new Chiba Yakult Plant construction plan, planned investment was increased from the previous ¥35 billion to ¥51.835 billion. Work is scheduled to begin in 2024 and completion in 2027, with daily production capacity of 2.6 million bottles. - FY2023AdvancedAnnual report
「Capital expenditures for the fiscal year focused primarily on the construction and upgrading of production facilities, totaling ¥32,579 million.」
Capital expenditures totaled ¥32,579 million, with expansion of production facilities for Yakult 1000 and Y1000 in Japan and investment in Wuxi Plant No. 2 and other facilities overseas. - FY2023-Q3RestatedAnnual report
「Planned investment 35,000 Internal funds Borrowings Leases 2024 2027 Daily production capacity 2.6 million bottles」
The company has continued to disclose the plan for a new Chiba Yakult Plant, involving planned investment of ¥35 billion, work commencing in 2024, completion scheduled for 2027 and daily production capacity of 2.6 million bottles. - FY2023-Q2AdvancedAnnual report
「Investment amount ¥35 billion (planned)」 Construction start Summer 2024 (planned)」 Start of operations Spring 2027 (planned)」 Production capacity 2.6 million bottles/day (at start of operations)」
The company approved a plan to build a next-generation plant in connection with the relocation of Chiba Yakult Plant. Construction is scheduled to start in summer 2024 and operations in spring 2027, with planned investment of ¥35 billion and production capacity of 2.6 million bottles per day. - FY2023-Q1AdvancedAnnual report
「By product, efforts progressed to establish a higher-production system in response to shortages of Yakult 1000 and Y1000.」
The company progressed efforts to establish a higher-production system in response to shortages of its core products. - FY2022AdvancedAnnual report
「Capital expenditures for the fiscal year focused primarily on the construction and upgrading of production facilities, totaling ¥26,092 million.」
Capital expenditures totaled ¥26.092 billion. Overseas, ¥16.578 billion was invested mainly in Foshan Plant and Wuxi Plant No. 2. The plan for Wuxi Plant No. 2 continued to target completion in September 2022 and daily production capacity of 800,000 bottles. - FY2022-Q1AdvancedAnnual report
「In the Philippines, at Philippine Yakult Co., Ltd., an equity-method affiliate, construction began in June on Plant No. 2 to produce the fermented milk beverages Yakult and Yakult Light.」
Construction began on Plant No. 2 in the Philippines to produce Yakult and other products, marking concrete progress in strengthening the production base. - FY2021SoftenedAnnual report
「Construction of Plant No. 2 13,285 3,321 Internal funds November 2020 September 2022 Daily production capacity of 800,000 bottles」
For Wuxi Yakult Plant No. 2, the company disclosed total investment of ¥13.285 billion, payments made to date of ¥3.321 billion, scheduled completion in September 2022 and daily production capacity of 800,000 bottles. The completion date was changed from the previous schedule to September 2022. - FY2021-Q2RestatedAnnual report
「Cash flow from investing activities was ¥4,595 million, as proceeds from the redemption of time deposits outweighed the acquisition of fixed assets through the expansion and upgrading of production facilities, representing an increase of ¥4,246 million in inflows year on year.」
The company has continued to acquire fixed assets in connection with the expansion and upgrading of production facilities. It also stated that there had been no significant changes in plans for major facilities. - FY2021-Q1RestatedAnnual report
「In addition to expanding the sales organization, researching and developing new products, and upgrading production facilities, we actively pursued our international and pharmaceutical businesses and worked to improve business performance.」
Production facility upgrades have been described as an ongoing initiative alongside the sales organization, new products, international business and pharmaceutical business. - FY2020AdvancedAnnual report
「Construction of Plant No. 2 13,285 — Internal funds August 2020 April 2022 Daily production capacity of 800,000 bottles」
A total of ¥20,631 million was invested in production, research and other facilities during the fiscal year. The equipment plan for Wuxi Yakult Plant No. 2 called for total investment of ¥13.285 billion, completion in April 2022 and daily production capacity of 800,000 bottles. - FY2020-Q3RestatedAnnual report
「In addition to expanding the sales organization, researching and developing new products, and upgrading production facilities, we actively pursued our international and pharmaceutical businesses and worked to improve business performance.」
Production facility upgrades have continued as an initiative alongside the sales organization, new products, international business and pharmaceutical business. The company stated that there had been no significant changes in major facilities. - FY2020-Q2RestatedAnnual report
「Cash flow from investing activities was ¥349 million, as proceeds from the redemption of time deposits outweighed the acquisition of fixed assets through the construction, expansion and upgrading of production facilities, representing a decrease of ¥13,748 million in outflows year on year.」
The company has continued to acquire fixed assets in connection with the construction, expansion and upgrading of production facilities. - FY2020-Q1RestatedAnnual report
「In addition to expanding the sales organization, researching and developing new products, and upgrading production facilities, we actively pursued our international and pharmaceutical businesses and worked to improve business performance.」
Production facility upgrades have continued as an initiative alongside the sales organization, new products, international business and pharmaceutical business. - FY2019AdvancedAnnual report
「Capital expenditures for the fiscal year focused primarily on the construction and expansion of production facilities, totaling ¥29,505 million.」
Capital expenditures totaled ¥29,505 million, with construction and expansion progressing overseas at the Foshan plant, Wuxi Plant No. 2 and production facilities in Indonesia. - FY2019-Q3RestatedAnnual report
「In addition to expanding the sales organization, researching and developing new products, and upgrading production facilities, we actively pursued our international and pharmaceutical businesses and worked to improve business performance.」
Production facility upgrades have continued as an initiative alongside the expanded sales organization, new products, international business and pharmaceutical business. The company stated that there had been no significant changes in major facilities. - FY2019-Q2RestatedAnnual report
「Cash flow from investing activities was negative ¥13,399 million, mainly due to placements of time deposits and the acquisition of fixed assets through the construction, expansion and upgrading of production facilities, representing a decrease of ¥1,242 million in outflows year on year.」
The company has continued to acquire fixed assets in connection with the construction, expansion and upgrading of production facilities. - FY2019-Q1RestatedAnnual report
「In addition to expanding the sales organization, researching and developing new products, and upgrading production facilities, we actively pursued our international and pharmaceutical businesses and worked to improve business performance.」
Production facility upgrades have continued as an initiative alongside the sales organization, new products, international business and pharmaceutical business. - FY2018AdvancedAnnual report
「Capital expenditures for the fiscal year focused primarily on the construction and expansion of production facilities, totaling ¥23,304 million.」
A total of ¥23.304 billion was invested, primarily in the construction and expansion of production facilities, including ¥12.4 billion invested overseas in facilities in Myanmar, Indonesia and Guangzhou. - FY2018-Q3RestatedAnnual report
「In addition to expanding the sales organization, researching and developing new products, and upgrading production facilities, we actively pursued our international and pharmaceutical businesses and worked to improve business performance.」
Production facility upgrades have continued as an initiative alongside the sales organization, new products, international business and pharmaceutical business. - FY2018-Q2RestatedAnnual report
「Cash flow from investing activities was negative ¥14,641 million, mainly due to placements of time deposits and the acquisition of fixed assets through the construction, expansion and upgrading of production facilities, representing a decrease of ¥15,946 million in outflows year on year.」
The company has continued to acquire fixed assets in connection with the construction, expansion and upgrading of production facilities. - FY2018-Q1RestatedAnnual report
「In addition to expanding the sales organization, researching and developing new products, and upgrading production facilities, we actively pursued our international and pharmaceutical businesses and worked to improve business performance.」
Production facility upgrades have continued as an initiative alongside the sales organization, new products, international business and pharmaceutical business. The company stated that there had been no significant changes in major facilities. - FY2017AdvancedAnnual report
「Capital expenditures for the fiscal year focused primarily on upgrading production and research and development facilities, totaling ¥23,365 million.」
A total of ¥23.365 billion was invested, primarily in upgrading production and research facilities, while production facilities in Guangzhou and Indonesia were also expanded overseas. - FY2017-Q3RestatedAnnual report
「In addition to expanding the sales organization, researching and developing new products, and upgrading production facilities, we actively pursued our international and pharmaceutical businesses and worked to improve business performance.」
Production facility upgrades have continued as an initiative alongside the sales organization, new products, international business and pharmaceutical business. - FY2017-Q2AdvancedAnnual report
「Cash flow from investing activities was negative ¥30,588 million, mainly due to placements of time deposits and the acquisition of fixed assets through the construction, expansion and upgrading of production facilities, representing an increase of ¥5,846 million in outflows year on year.」
The company continued to acquire fixed assets in connection with the construction, expansion and upgrading of production facilities, resulting in investing cash outflows of ¥30,588 million. - FY2017-Q1First statedAnnual report
「In addition to expanding the sales organization, researching and developing new products, and upgrading production facilities, we actively pursued our international and pharmaceutical businesses and worked to improve business performance.」
The company cited production facility upgrades as an initiative alongside the sales organization, new products, international business and pharmaceutical business.